Progress report on vindesine treatment of melphalan-resistant multiple myeloma

Since 1979 the authors treated patients with melphalan resistant multiple myeloma with a vindesine prednisone combination. For three consecutive weeks vindesine was administered weekly (2 mg/m super(2)) followed by prednisone (100 mg orally for 5 days/weeks). Response was evaluated after two cycles...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	European journal of cancer & clinical oncology 1983-01, Vol.19 (6), p.861-862
Hauptverfasser:	Van Dobbenburgh, O.A., Houwen, B., Halie, M.R., Marrink, J., Ockhuizen, Th, Nieweg, H.O.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - administration & dosage Drug Resistance Drug Therapy, Combination Humans Melphalan - therapeutic use Multiple Myeloma - drug therapy Prednisone - administration & dosage Vinblastine - administration & dosage Vinblastine - analogs & derivatives Vindesine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!